Lambert-Eaton myasthenic syndrome (LEMS)

From Aaushi
Jump to navigation Jump to search

Etiology

Epidemiology

Pathology

Clinical manifestations

Laboratory

Diagnostic procedures

Management

More general terms

Additional terms

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 640
  2. 2.0 2.1 2.2 2.3 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 18. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018.
  3. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 624
  4. Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
  5. 5.0 5.1 Sabater L et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008 Mar 18; 70:924 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18032743
    Lang B and Evoli A. SOX1 autoantibodies: Tumor markers in LEMS patients? Neurology 2008 Mar 18; 70:906 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18347313
  6. 6.0 6.1 Payne M, Bradbury P, Lang B et al Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol. 2010 Jan;5(1):34-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19934775
  7. Petty R Lambert Eaton myasthenic syndrome. Pract Neurol. 2007 Aug;7(4):265-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17636143
  8. Sanders DB, Guptill JT. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn). 2014 Oct;20 (5 Peripheral Nervous System Disorders):1413-25. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2529929

Patient information

Lambert-Eaton myasthenic syndrome patient information